Answers are grounded in this paper and cite their sources.
The investigational HFS bioproduct proved to be safe and non-immunogenic with a good preliminary efficacy for the treatment of CVU, according to the protocol and doses proposed. A multicentric phase III clinical trial will be necessary to verify these findings.
No takes yet. Share an insight, caveat, or question.
Abbade et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: